Zsofia K. Stadler, MD, has been appointed as the next Editor-in-Chief of JCO Precision Oncology (JCO PO), a journal of the American Society of Clinical Oncology (ASCO). The appointment is scheduled to take effect on July 1, 2026.
JCO Precision Oncology is a peer-reviewed, online-only journal that publishes original research, reports, opinions, and reviews focused on precision oncology and genomics- and other biomarker-driven clinical care for patients with cancer.
According to ASCO, the appointment reflects experience in precision oncology and engagement with data and technology in cancer care. The incoming Editor-in-Chief serves as an Attending Physician and Clinic Director of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center (MSK) and holds a secondary appointment in the Gastrointestinal Medical Oncology Service. The role also includes a professorship in medicine at Weill Cornell Medical College, with clinical expertise in inherited cancer predispositions, including Lynch syndrome.
The appointee serves as co-principal investigator of Memorial Sloan Kettering Cancer Center’s tumor-normal IMPACT sequencing protocol and received the 2025 American Association for Cancer Research Team Science Award for that work. Research activities, supported by the National Institutes of Health and multiple foundations, focus on identifying cancer susceptibility genes and developing screening strategies for high-risk families using genomic technologies.
The incoming Editor-in-Chief completed medical training at Cornell University and post-graduate fellowships at Harvard University’s Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center. Service with JCO Precision Oncology has included roles on the Editorial Board and as an Associate Editor since the journal’s inception, along with annual recognition as a Top Doctor by New York Magazine since 2019.
According to the appointee, priorities include building on the journal’s existing foundation, translating complex genomic and artificial intelligence data into actionable insights, advancing biologically informed therapeutics, and supporting equitable implementation of precision oncology worldwide.
Click here to read the original press release.
